Clinical trial
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy…
NCT00003583 · University of Florida, Other · Unknown status
Key facts
| NCT number | NCT00003583 |
|---|---|
| Title | Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer |
| Official title | A Phase II Trial Using Amifostine as a Chemo/Radio Protective Agent in the Treatment of Limited Stage Small-Cell Lung Cancer |
| Lead sponsor | University of Florida, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity |
| Intervention type | Drug, Radiation |
| Interventions | amifostine trihydrate, cisplatin, etoposide, radiation therapy |
| Enrollment | 20 |
| Start date | Jun 1, 1997 |
| First posted | Apr 30, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: